On February 17, 2026, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital administered the PF-08634404 in combination with investigational drug “Novel-Novel Combination”, developed by Pfizer — to the “first patient in the World ” as part of a global, multicenter First-in-Human Phase 1 Clinical Trial (ClinicalTrials.gov ID: NCT07227298).  The administration took place in Kansai Medical University Hospital.                                                                                                                                     Study Details | NCT07227298 | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | ClinicalTrials.gov